KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

Market: Pharmaceuticals and Healthcare

Global, 28 pages report, published by GlobalData

Report ThumbnailOctober-2018
KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents

Summary

This KOL Insight briefing focuses on KOLs views of recent & upcoming data for key HBV pipeline agents.

Questions topics -
- Further Phase I data required for Roche’s capsid inhibitor RO7049389
- Replicor’s US trial plans and transition from IV to subcutaneous REP 2139
- Efficacy of Spring Bank’s inarigivir at 100mg in the Phase II ACHIEVE trial
- Expected role for inarigivir in HBV
- Efficacy of Arbut

Read More
  • Table of Contents
  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications
  • Appendix
Read More

Please select a license type

Share

Related Products

GlobalDataKOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agentsProduct ThumbnailKOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents, Industry ReportProduct #: 1194169
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2019 Global Market Analyst. All Rights Reserved